Company profile
Finch Therapeutics Group, Inc.
OTC: FNCH · Healthcare · Biotechnology
#1045 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 39GM —SS 24
v0.1 · 25/100 weight · pillars only
↑ filing timeliness, balance-sheet leverage · ↓ workforce scale, operating margin
Methodology →Revenue TTM
$2.8M
Rev growth YoY (TTM)
+1024.5%
Net income (FY)
-$74.8M
Employees
1
as of 2026-08-22
Market cap
$16.4M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$107.0k$107.0k2023
Net income-$74.8M-$74.8M2023
Operating income-$83.9M-$83.9M2023
Total assets$55.4M$55.4M2023
Liabilities$32.5M$32.5M2023
Equity$22.9M$22.9M2023
Revenue trend
FY2021 – FY2023 · USD
FY21
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2022
By product
Collaboration Revenue100%
By geography
Not disclosed.
The read
What is Finch Therapeutics Group, Inc.’s revenue?
Finch Therapeutics Group, Inc. booked $107.0k in FY2023 revenue, contracting 88% year over year — slower than 90% of Healthcare companies we track, at a -69863.6% net margin.
Peers · Healthcare
Forza Innovations Inc.——Biostax Corp.——BioMark Diagnostics Inc.——Meridian Holdings, Inc.——Profusa, Inc. Common Stock9DTherapeutic Solutions International, Inc.——Neighbors
Suffolk →Key facts
CEOMatthew Blischak
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeOTC: FNCH
Employees1
IPO date2021-03-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.